United Therapeutics CFO exercises options, sells shares
Rhea-AI Filing Summary
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share and, on the same date, sold 10,000 shares in multiple open-market trades at reported prices such as $518.2830, $529.0430 and $536.2750 per share. Following these transactions, he directly holds 18,876 shares of common stock. The exercise and subsequent sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($3.92M approx. pre-tax spread)
Exercise and Sale
19 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
10,000 shs ($5.27M)
Approx. gross sale proceeds
$5.27M
Approx. exercise cost
$1.35M
Approx. pre-tax spread
$3.92M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,000 | $135.42 | $1.35M |
| Sale | Common Stock | 200 | $518.283 | $104K |
| Sale | Common Stock | 640 | $519.3025 | $332K |
| Sale | Common Stock | 875 | $520.6164 | $456K |
| Sale | Common Stock | 905 | $521.4662 | $472K |
| Sale | Common Stock | 200 | $522.3645 | $104K |
| Sale | Common Stock | 440 | $524.2001 | $231K |
| Sale | Common Stock | 320 | $525.37 | $168K |
| Sale | Common Stock | 520 | $526.5726 | $274K |
| Sale | Common Stock | 80 | $527.4931 | $42K |
| Sale | Common Stock | 2,620 | $529.043 | $1.39M |
| Sale | Common Stock | 577 | $530.6366 | $306K |
| Sale | Common Stock | 587 | $531.4904 | $312K |
| Sale | Common Stock | 288 | $532.5947 | $153K |
| Sale | Common Stock | 642 | $533.5959 | $343K |
| Sale | Common Stock | 506 | $534.5972 | $271K |
| Sale | Common Stock | 440 | $535.3358 | $236K |
| Sale | Common Stock | 160 | $536.275 | $86K |
Holdings After Transaction:
Stock Option — 152,500 contracts (Direct);
Common Stock — 18,876 shares (Direct)
Footnotes (18)
- F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
- F10. This transaction was executed in multiple trades at prices ranging from $527.13 to $528.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $529.02 to $530.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. This transaction was executed in multiple trades at prices ranging from $530.05 to $530.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13. This transaction was executed in multiple trades at prices ranging from $531.08 to $532.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F14. This transaction was executed in multiple trades at prices ranging from $532.09 to $533.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F15. This transaction was executed in multiple trades at prices ranging from $533.09 to $534.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F16. This transaction was executed in multiple trades at prices ranging from $534.12 to $535.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F17. This transaction was executed in multiple trades at prices ranging from $535.14 to $536.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F18. This transaction was executed in multiple trades at prices ranging from $536.15 to $536.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2. This transaction was executed in multiple trades at prices ranging from $517.82 to $518.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $518.89 to $519.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $519.98 to $520.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $520.99 to $521.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $522.04 to $522.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $523.85 to $524.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $524.98 to $525.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $526.09 to $526.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did United Therapeutics (UTHR) CFO James Edgemond report in this Form 4?
CFO James Edgemond reported exercising options for 10,000 United Therapeutics shares at $135.42 each, then selling 10,000 shares in multiple open-market trades. After these transactions, he directly owns 18,876 common shares, all disclosed for March 23, 2026.
Were the United Therapeutics (UTHR) CFO’s trades under a Rule 10b5-1 plan?
Yes. The option exercise and subsequent share sales were conducted under a Rule 10b5-1 trading plan. The footnotes state the plan was entered into on October 31, 2025, indicating these transactions were pre-arranged rather than newly decided at the trade date.
What type of derivative did the United Therapeutics (UTHR) CFO exercise?
He exercised a stock option covering 10,000 shares of United Therapeutics common stock at an exercise price of $135.42 per share. This derivative transaction converted the option into common shares, which were then sold in open-market trades reported in the same Form 4 filing.
Does the Form 4 show net buying or net selling by the United Therapeutics (UTHR) CFO?
The Form 4 shows an option exercise for 10,000 shares and open-market sales totaling 10,000 shares, resulting in a net-sell share balance for the period. Despite the sales, the CFO retains 18,876 United Therapeutics common shares held directly after these transactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.